News

Autologous therapies are therapies that are derived from the patient and as such they exhibit certain specific requirements. The scope of such therapies differs greatly from what we usually see in the biopharma industry, and they require special handling and care. The quantities are much smaller than usual, but nonetheless they need to be shipped in a highly sterile and protected manner.

According to information from the biopharmaceutical industry, the loss rate for CAR-T cell therapies is over 1%. This means that it can be assumed that currently only 99 out of 100 people receive a fully functional Car-T therapy. Read here!

The National Health Service (NHS) of Great Britain, confirms the use of CAR-T Cell Therapy Kymriah on an 11-year-old leukaemia patient. However, it is not certain whether the vital therapy will make its way into society. Read it for yourself!
 

Due to increased efficiency, flexibility and cost reduction, it has become standard practice to use integrated single use freeze-thaw systems with single use bags, tubing and connectors. Find out what the reasons for this are here!

In November, Single Use Support GmbH Founder Johannes Kirchmaier presented the company newest development, the MITS.2D at the U.S. Food and Drug Administration (FDA) headquarters in Washington to more than 60 industry experts.

As is the case with a number of developments, a spontaneous idea and the will to shake things up led to something big. Two young entrepreneurs from Tyrol, Austria, took on the challenge to “hack” the biopharma logistics process, or, in other words, to reinvent if not revolutionize it.
 

It all starts with a grain of sand that by chance found its way into the oyster. The grain of sand is an annoyance; it poses a problem. The oyster feels disturbed so it deals with the intruder. But how does the oyster go about it – how does the oyster save its problem?